Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.

  title={Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.},
  author={Ken-Ichi Fujita and Yasutsuna Sasaki},
  journal={Drug metabolism and pharmacokinetics},
  volume={29 1},
  Cytotoxic anticancer drugs are the most challenging therapeutic agents among all medicines with relatively narrow efficacy profiles. Therefore, medical oncologists have to practically manage the risk of severe toxic effects to optimize treatment outcomes. Dose and treatment-schedule recommendations for cytotoxic anticancer agents are determined on the basis of clinical trials. Patients enrolled in clinical trials are those likely to receive the drug in clinical practice, excluding those with… 

Figures from this paper

Strategies for Incorporating Pharmacokinetic Studies into Oncology Phase I Trials

This chapter discusses PK concepts specific to clinical drug development of oncology drugs, application of PK in specific situations and drug interactions, and practical issues in designing PK studies in Phase I trials.

Phase I Oncology Drug Development

This chapter reviews the critical steps enabling the early phase clinical development from the perspective of a pharmaceutical drug developer.

Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer

The incidence rate of irinotecan-induced cholinergic syndrome increased concomitantly with the addition of cytotoxic chemotherapeutic agents administered.

Status and Challenges of Plant-Anticancer Compounds in Cancer Treatment

Although more research is still necessary to develop more efficient and safe phytochemical drugs, more of these compounds might be used in future cancer therapies, as some strategies to face the limitations have been considered.

Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface area.

To confirm the equal efficacy of TKIs in patients undergoing a dose reduction, prospective observational studies with less patient heterogeneity are required.

Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group.

Dose-reduction estimation studies for TKIs may be crucial, particularly for patients with a low BSA, and confirmation of these results in population-based retrospective ones investigating the incidence of dose reduction in patients with AEs and those withLow BSA may be required for the efficient use of erlotinib in common clinical practice.

Compliance of Patients with Locally Advanced Colorectal Cancer to Chemotherapy Using FOLFOX compared to XELOX Regimen

Introduction. Adjuvant chemotherapy become the treatment of choice in advance colorectal cancer to prevent recurrence. Studies showed that FOLFOX and XELOX regimen has been proven to increase overall

Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38

Investigation of the potential for pazopanib to inhibit UDP-glucuronosyltransferase (UGT)1A1 and organic anion-transporting polypeptide (OATP)1B1, which are involved in detoxification and hepatic uptake of SN-38, showed that the drug–drug interaction is at least partially mediated by inhibition of UGT1A 1.

PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment

These ‘real-world’ data obtained applying UKPDS RE may reflect patients’ and clinicians’ interest in realizing individual CV risk, and its evolution, when applied to patients on persistent sitagliptin treatment.



Chemotherapy dosing in overweight and obese patients with cancer

Pharmacokinetic studies support the use of actual body weight to calculate chemotherapy doses for most chemotherapy drugs in obese patients, and recommend that, after considering any accompanying comorbidities, chemotherapy dosing should be calculated based on body surface area using actual weight, rather than an estimate or idealization of weight.

Evidence for therapeutic drug monitoring of targeted anticancer therapies.

Although the current evidence is insufficient to mandate TDM in routine practice, a concerted investigation should be encouraged to determine whether the steady-state trough measurements of targeted agents will have a practical place in the clinical care of patients with cancer.

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

  • J. GriggsP. Mangu G. Lyman
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
Full weight-based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure, and the use of fixed-dose chemotherapy is rarely justified.

International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

Clinical trials need to incorporate an analysis of chemotherapy in terms of the pharmacokinetic and pharmacodynamic effects of aging, and data already accumulated need to be reanalyzed by age to aid in the management of the older cancer patient.

Pharmacokinetics of chemotherapy in the older patient.

Multicenter pharmacokinetic studies of adequate sample size, which include a thorough evaluation of physiologic factors and geriatric assessment parameters, would provide further insight into the factors affecting treatment tolerance.

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

The combination of S-1 and oxaliplatin appears to be active and well tolerated in patients with metastatic biliary cancer, and thus is feasible as a therapeutic modality, despite differences in 5-FU exposure.

Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.

Dosing adjustments are often necessary in HD cancer patients in terms of dosage adjustment and time of administration regarding the dialysis sessions to optimize cytotoxic drug therapy in those patients.

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

Individual FU dose adjustment based on pharmacokinetically guided monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities.